A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide ("CPP") technology platform. Our lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name ("INN") and the United States Adopted Name ("USAN") for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich's ataxia (“FA”). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Currently, there are no treatment options that address the core deficit of FA, low levels of FXN. Nomlabofusp represents the first potential therapy designed to increase FXN levels in patients with FA.
| Metric | TTM | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -132M | -45M | -61M | -52M | -58M | -74M |
| EPS | $-1.96 | $-1.22 | $-1.90 | $-1.90 | $-2.12 | $-2.78 |
| Free Cash Flow | 0 | -42M | -52M | -44M | -53M | -60M |
| ROIC | -58.9% | -73.1% | -56.6% | -53.0% | -46.3% | -43.0% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.43 | 0.28 | 0.30 | 0.09 | 0.06 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -140M | -46M | -61M | -53M | -58M | -74M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -94.9% | -61.8% | -65.8% | -66.5% | -47.5% | -43.9% |
| Shares Outstanding | 86M | 37M | 32M | 27M | 27M | 27M |
| Metric | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 12M | 9.6M | 27M | 55M | 40M | 41M | 48M | 24M | 122M |
| SG&A | 2.2M | 4.2M | 8.1M | 19M | 18M | 12M | 13M | 16M | 18M |
| EBIT | -14M | -14M | -36M | -74M | -58M | -53M | -61M | -46M | -140M |
| Op. Margin | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | N/A | N/A | -37M | -74M | -58M | -52M | -61M | -45M | -132M |
| Net Margin | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 1.4M | 1.4M | 1.4M | 5.6M | 0 |
| Returns on Capital | |||||||||
| ROIC | N/A | N/A | -35.0% | -43.0% | -46.3% | -53.0% | -56.6% | -73.1% | -58.9% |
| ROE | N/A | N/A | -203.9% | -43.9% | -47.5% | -66.5% | -65.8% | -61.8% | -94.9% |
| ROA | N/A | N/A | -47.0% | -39.3% | -44.0% | -49.3% | -50.4% | -44.8% | -70.5% |
| Cash Flow | |||||||||
| Op. Cash Flow | -14M | -15M | -28M | -60M | -52M | -44M | -51M | -41M | 0 |
| Free Cash Flow | -14M | -15M | -28M | -60M | -53M | -44M | -52M | -42M | 0 |
| Owner Earnings | -14M | -15M | -30M | -68M | -62M | -52M | -61M | -47M | -8.2M |
| CapEx | 2K | 17K | 58K | 595K | 660K | 55K | 108K | 764K | 270K |
| Maint. CapEx | 11K | 34K | 50K | 70K | 212K | 188K | 261K | 263K | 340K |
| Growth CapEx | 0 | 0 | 8K | 525K | 448K | 0 | 0 | 501K | 0 |
| D&A | 11K | 34K | 50K | 70K | 212K | 188K | 261K | 263K | 340K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 121K | 395K | 1.6M | 8.6M | 10M | 8.3M | 9.6M | 5.5M | 7.9M |
| Debt Repayment | 0 | 0 | 49K | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||
| Net Debt | N/A | -36M | -113M | -176M | -119M | -78M | -92M | -47M | -175M |
| Cash & Equiv. | 9.9M | 36M | 58M | 36M | 32M | 41M | 49M | 27M | 175M |
| Long-Term Debt | N/A | N/A | N/A | 3.5M | 3.2M | 20M | 15M | 8.5M | 8.5M |
| Debt/Equity | -0.00 | 0.00 | 0.02 | 0.06 | 0.09 | 0.30 | 0.28 | 0.43 | 0.00 |
| Interest Coverage | -142.2 | N/A | -40.8 | -91.6 | -110.1 | -321.2 | -32.2 | -25.9 | -25.9 |
| Equity | -55M | -69M | 104M | 169M | 122M | 78M | 93M | 54M | 139M |
| Total Assets | 269K | 38M | 118M | 189M | 132M | 106M | 122M | 81M | 187M |
| Total Liabilities | 234K | 2.9M | 13M | 20M | 9.9M | 27M | 28M | 27M | 48M |
| Intangibles | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | -69M | -105M | -180M | -238M | -290M | -351M | -396M | -372M |
| Working Capital | N/A | 34M | 110M | 172M | 121M | 98M | 108M | 59M | 138M |
| Current Assets | N/A | 37M | 117M | 188M | 131M | 105M | 121M | 72M | 183M |
| Current Liabilities | N/A | 2.9M | 6.9M | 17M | 9.9M | 7.3M | 13M | 12M | 45M |
| Per Share Data | |||||||||
| EPS | -19.65 | -19.53 | -3.00 | -2.78 | -2.12 | -1.90 | -1.90 | -1.22 | -1.96 |
| Owner EPS | N/A | -21.16 | -2.45 | -2.55 | -2.28 | -1.91 | -1.90 | -1.25 | -0.10 |
| Book Value | N/A | -94.02 | 8.57 | 6.33 | 4.46 | 2.86 | 2.89 | 1.44 | 1.62 |
| Cash Flow/Share | N/A | -20.57 | -2.32 | -2.23 | -1.90 | -1.60 | -1.59 | -1.10 | -1.54 |
| Dividends/Share | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | N/A | 0.7M | 12.2M | 26.7M | 27.3M | 27.4M | 32.3M | 37.2M | 85.6M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 44.6 | 12.5 | 9.1 | 20.0 | 20.7 | 9.7 | 3.0 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | -0.6% | -2.8% | -4.8% | -2.8% | -2.7% | -8.0% | N/A |
| Market Cap | 0 | N/A | 4.7B | 2.1B | 1.1B | 1.6B | 1.9B | 518M | 416M |
| Avg. Price | 0.00 | N/A | 238.91 | 378.32 | 61.22 | 46.73 | 97.32 | 24.65 | 4.86 |
| Year-End Price | 0.00 | N/A | 382.08 | 79.08 | 40.44 | 57.00 | 59.76 | 13.92 | 4.86 |
Larimar Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Larimar Therapeutics, Inc. (LRMR) has a 5-year average return on invested capital (ROIC) of -54.4%. This is below average and may indicate limited pricing power.
Larimar Therapeutics, Inc. (LRMR) has a market capitalization of $416M. It is classified as a small-cap stock.
Larimar Therapeutics, Inc. (LRMR) does not currently pay a regular dividend.
Larimar Therapeutics, Inc. (LRMR) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Larimar Therapeutics, Inc. (LRMR) generated $-42 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Larimar Therapeutics, Inc. (LRMR) has a debt-to-equity ratio of 0.43. This indicates a conservatively financed balance sheet.
Larimar Therapeutics, Inc. (LRMR) reported earnings per share (EPS) of $-1.22 in its most recent fiscal year.
Larimar Therapeutics, Inc. (LRMR) has a return on equity (ROE) of -61.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 8 years of financial data for Larimar Therapeutics, Inc. (LRMR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Larimar Therapeutics, Inc. (LRMR) has a book value per share of $1.44, based on its most recent annual SEC filing.